Shares of Biogen Idec Inc. and partner Dublin, Ireland-based Elan Corp. plc took a hit Friday after news of a European review disclosed a higher number of PML cases linked to multiple sclerosis drug Tysabri (natalizumab) than previously reported. (BioWorld Today) Read More